Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells. (May 2020)

• Record Type: Journal Article
• Authors: Wei, Pei; Zhang, Zhainan; Lin, Mao; Zhou, Bin; Wang, Zhiyong
• Is Part Of: Cytokine. Volume 129(2020)
• Publication Date: 2020-05
• Subjects: Vascular endothelial growth factor -- Basic fibroblast growth factor -- Bevacizumab -- Glioma; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2020.155022
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: Bevacizumab has bidirectional regulatory effects on the secretion of bFGF. Moderate VEGF neutralization reduced bFGF production in glioma cells. VEGF overblocking enhanced bFGF secretion in glioma cells. Abstract: Previous studies suggest that upregulated basic fibroblast growth factor (bFGF) plays a key role in the resistance to anti-vascular endothelial growth factor (VEGF) therapy in glioma. This study reported that anti-VEGF treatment regulated bFGF secretion in a double-edged manner. That is, moderate VEGF neutralization reduced bFGF production, whereas VEGF overblocking enhanced bFGF secretion in glioma cells. Our data provide a new perspective on the treatment of glioma with anti-VEGF, and the underlying mechanism is worthy of further study.